The pharmacogenetics of carboxylesterases: CES1 and CES2 genetic variants and their clinical effect

Drug Metabolism and Drug Interactions

Volumn 29, Issue 3, 2014, Pages 143-151

  Merali, Zahra ^a   Ross, Stephanie ^b,c   Paré, Guillaume ^b,c,d  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^b MCMASTER UNIVERSITY   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

^d MCMASTER UNIVERSITY   (Canada)

Author keywords

Aspirin; Carboxylesterase; Carboxylesterase 1; Carboxylesterase 2; Clopidogrel; Dabigatran etexilate; Gene function; Imidapril; Irinotecan; Methylphenidate; Oseltamivir; Pharmacogenetics

Indexed keywords

ACETYLSALICYLIC ACID; CARBOXYLESTERASE; CARBOXYLESTERASE 1; CARBOXYLESTERASE 2; CLOPIDOGREL; DABIGATRAN ETEXILATE; IMIDAPRIL; IRINOTECAN; METHYLPHENIDATE; OSELTAMIVIR; UNCLASSIFIED DRUG; ANTITHROMBOCYTIC AGENT; ANTIVIRUS AGENT; BENZIMIDAZOLE DERIVATIVE; BLOOD CLOTTING FACTOR 10A INHIBITOR; CAMPTOTHECIN; CENTRAL STIMULANT AGENT; CES1 PROTEIN, HUMAN; CES2 PROTEIN, HUMAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IMIDAZOLIDINE DERIVATIVE; ISOENZYME; PYRIDINE DERIVATIVE; TICLOPIDINE;

BIOTRANSFORMATION; BLEEDING; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG METABOLISM; ENZYME STRUCTURE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; HYPERTENSION; NONHUMAN; PHARMACOGENETICS; REVIEW; ANALOGS AND DERIVATIVES; CHEMISTRY; GENETICS; METABOLISM; PHYSIOLOGY;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIVIRAL AGENTS; ASPIRIN; BENZIMIDAZOLES; CAMPTOTHECIN; CARBOXYLESTERASE; CARBOXYLIC ESTER HYDROLASES; CENTRAL NERVOUS SYSTEM STIMULANTS; FACTOR XA INHIBITORS; GENOTYPE; HUMANS; IMIDAZOLIDINES; ISOENZYMES; METHYLPHENIDATE; OSELTAMIVIR; PLATELET AGGREGATION INHIBITORS; POLYMORPHISM, GENETIC; PYRIDINES; TICLOPIDINE;

EID: 84919786525     PISSN: 07925077     EISSN: 21910162     Source Type: Journal    
DOI: 10.1515/dmdi-2014-0009     Document Type: Review

References (58)

1. Zhu HJ, Patrick KS, Yuan HJ, Wang JS, Donovan JL, DeVane CL, et al. Two CES1 gene mutations lead to dysfunctional carboxylesterase 1 activity in man: clinical significance and molecular basis. Am J Hum Genet 2008;82:1241-8.
2. Thomsen R, Rasmussen HB, Linnet K. In vitro drug metabolism by human carboxylesterase 1: focus on angiotensin-converting enzyme inhibitors. Drug Metab Dispos 2014;42:126-33.
3. Ishizuka T, Yoshigae Y, Murayama N, Izumi T. Different hydrolases involved in bioactivation of prodrug-type angiotensin receptor blockers: carboxymethylenebutenolidase and carboxylesterase 1. Drug Metab Dispos 2013;41:1888-95.
4. Imai T, Takase Y, Iwase H, Hashimoto M. Involvement of carboxylesterase in hydrolysis of propranolol prodrug during permeation across rat skin. Pharmaceutics 2013;5:371-84.
5. Kim MJ, Jeong ES, Park JS, Lee SJ, Ghim JL, Choi CS, et al. Multiple cytochrome P450 isoforms are involved in the generation of a pharmacologically active thiol metabolite, whereas paraoxonase 1 and carboxylesterase 1 catalyze the formation of a thiol metabolite isomer from ticlopidine. Drug Metab Dispos 2014;42:141-52.
6. Bencharit S, Morton CL, Xue Y, Potter PM, Redinbo MR. Structural basis of heroin and cocaine metabolism by a promiscuous human drug-processing enzyme. Nat Struct Biol 2003;10:349-56.
7. Xiao D, Shi D, Yang D, Barthel B, Koch TH, Yan B. Carboxylesterase-2 is a highly sensitive target of the antiobesity agent orlistat with profound implications in the activation of anticancer prodrugs. Biochem Pharmacol 2013;85:439-47.
8. Pratt SE, Durland-Busbice S, Shepard RL, Heinz-Taheny K, Iversen PW, Dantzig AH. Human carboxylesterase-2 hydrolyzes the prodrug of gemcitabine (LY2334737) and confers prodrug sensitivity to cancer cells. Clin Cancer Res 2013;19:1159-68.
9. Barthel BL, Zhang Z, Rudnicki DL, Coldren CD, Polinkovsky M, Sun H, et al. Preclinical efficacy of a carboxylesterase 2-activated prodrug of doxazolidine. J Med Chem 2009;52:7678-88.
10. Hosokawa M, Maki T, Satoh T. Characterization of molecular species of liver microsomal carboxylesterases of several animal species and humans. Arch Biochem Biophys 1990;277:219-27.
11. Fleming CD, Bencharit S, Edwards CC, Hyatt JL, Tsurkan L, Bai F, et al. Structural insights into drug processing by human carboxylesterase 1: tamoxifen, mevastatin, and inhibition by benzil. J Mol Biol 2005;352:165-77.
12. Ross MK, Borazjani A, Wang R, Crow JA, Xie S. Examination of the carboxylesterase phenotype in human liver. Arch Biochem Biophys 2012;522:44-56.
13. Satoh T, Hosokawa M. Structure, function and regulation of carboxylesterases. Chem Biol Interact 2006;162:195-211.
14. Taketani M, Shii M, Ohura K, Ninomiya S, Imai T. Carboxylesterase in the liver and small intestine of experimental animals and human. Life Sci 2007;81:924-32.
15. Bencharit S, Morton CL, Howard-Williams EL, Danks MK, Potter PM, Redinbo MR. Structural insights into CPT-11 activation by mammalian carboxylesterases. Nat Struct Biol 2002;9:337-42.
16. Tsurkan LG, Hatfield MJ, Edwards CC, Hyatt JL, Potter PM. Inhibition of human carboxylesterases hCE1 and hiCE by cholinesterase inhibitors. Chem Biol Interact 2013;203:226-30.
17. Zhao B, Bie J, Wang J, Marqueen SA, Ghosh S. Identification of a novel intracellular cholesteryl ester hydrolase (carboxylesterase 3) in human macrophages: compensatory increase in its expression after carboxylesterase 1 silencing. Am J Physiol Cell Physiol 2012;303:C427-35.
18. Holmes RS, Cox LA, Vandeberg JL. Mammalian carboxylesterase 5: comparative biochemistry and genomics. Comp Biochem Physiol D Genomics Proteomics 2008;3:195-204.
19. von HG. Patterns of amino acids near signal-sequence cleavage sites. Eur J Biochem 1983;133:17-21.
20. Zschunke F, Salmassi A, Kreipe H, Buck F, Parwaresch MR, Radzun HJ. cDNA cloning and characterization of human monocyte/macrophage serine esterase-1. Blood 1991;78:506-12.
21. Bencharit S, Morton CL, Hyatt JL, Kuhn P, Danks MK, Potter PM, et al. Crystal structure of human carboxylesterase 1 complexed with the Alzheimer's drug tacrine: from binding promiscuity to selective inhibition. Chem Biol 2003;10:341-9.
22. Friedrichsen M, Poulsen P, Wojtaszewski J, Hansen PR, Vaag A, Rasmussen HB. Carboxylesterase 1 gene duplication and mRNA expression in adipose tissue are linked to obesity and metabolic function. PLoS One 2013;8:e56861.
23. Langmann T, Becker A, Aslanidis C, Notka F, Ullrich H, Schwer H, et al. Structural organization and characterization of the promoter region of a human carboxylesterase gene. Biochim Biophys Acta 1997;1350:65-74.
24. Ghosh S, Natarajan R. Cloning of the human cholesteryl ester hydrolase promoter: identification of functional peroxisomal proliferator-activated receptor responsive elements. Biochem Biophys Res Commun 2001;284:1065-70.
25. Willer CJ, Schmidt EM, Sengupta S, Peloso GM, Gustafsson S, Kanoni S, et al. Discovery and refinement of loci associated with lipid levels. Nat Genet 2013;45:1274-83.
26. Zhu HJ, Brinda B, Froehlich TE, Markowitz JS. A discriminative analytical method for detection of CES1A1 and CES1A2/CES1A3 genetic variants. Pharmacogenet Genomics 2012;22:215-8.
27. Fukami T, Nakajima M, Maruichi T, Takahashi S, Takamiya M, Aoki Y, et al. Structure and characterization of human carboxylesterase 1A1, 1A2, and 1A3 genes. Pharmacogenet Genomics 2008;18:911-20.
28. Hosokawa M, Furihata T, Yaginuma Y, Yamamoto N, Watanabe N, Tsukada E, et al. Structural organization and characterization of the regulatory element of the human carboxylesterase (CES1A1 and CES1A2) genes. Drug Metab Pharmacokinet 2008;23:73-84.
29. Morgan EW, Yan B, Greenway D, Parkinson A. Regulation of two rat liver microsomal carboxylesterase isozymes: species differences, tissue distribution, and the effects of age, sex, and xenobiotic treatment of rats. Arch Biochem Biophys 1994;315:513-26.
30. Anand SS, Kim KB, Padilla S, Muralidhara S, Kim HJ, Fisher JW, et al. Ontogeny of hepatic and plasma metabolism of deltamethrin in vitro: role in age-dependent acute neurotoxicity. Drug Metab Dispos 2006;34:389-97.
31. Yang D, Pearce RE, Wang X, Gaedigk R, Wan YJ, Yan B. Human carboxylesterases HCE1 and HCE2: ontogenic expression, interindividual variability and differential hydrolysis of oseltamivir, aspirin, deltamethrin and permethrin. Biochem Pharmacol 2009;77:238-47.
32. Paré G, Eriksson N, Lehr T, Connolly S, Eikelboom J, Ezekowitz MD, et al. Genetic determinants of dabigatran plasma levels and their relation to bleeding. Circulation 2013;127:1404-12.
33. Nemoda Z, Angyal N, Tarnok Z, Gadoros J, Sasvari-Szekely M. Carboxylesterase 1 gene polymorphism and methylphenidate response in ADHD. Neuropharmacology 2009;57:731-3.
34. Zhu HJ, Appel DI, Jiang Y, Markowitz JS. Age- and sex-related expression and activity of carboxylesterase 1 and 2 in mouse and human liver. Drug Metab Dispos 2009;37:1819-25.
35. Tarkiainen EK, Backman JT, Neuvonen M, Neuvonen PJ, Schwab M, Niemi M. Carboxylesterase 1 polymorphism impairs oseltamivir bioactivation in humans. Clin Pharmacol Ther 2012;92:68-71.
36. Geshi E, Kimura T, Yoshimura M, Suzuki H, Koba S, Sakai T, et al. A single nucleotide polymorphism in the carboxylesterase gene is associated with the responsiveness to imidapril medication and the promoter activity. Hypertens Res 2005;28:719-25.
37. Lewis JP, Horenstein RB, Ryan K, O'Connell JR, Gibson Q, Mitchell BD, et al. The functional G143E variant of carboxylesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel response. Pharmacogenet Genomics 2013;23:1-8.
38. Tang M, Mukundan M, Yang J, Charpentier N, LeCluyse EL, Black C, et al. Antiplatelet agents aspirin and clopidogrel are hydrolyzed by distinct carboxylesterases, and clopidogrel is transesterificated in the presence of ethyl alcohol. J Pharmacol Exp Ther 2006;319:1467-76.
39. Kubo T, Kim SR, Sai K, Saito Y, Nakajima T, Matsumoto K, et al. Functional characterization of three naturally occurring single nucleotide polymorphisms in the CES2 gene encoding carboxylesterase 2 (HCE-2). Drug Metab Dispos 2005;33:1482-7.
40. Johnson AD, Handsaker RE, Pulit SL, Nizzari MM, O'Donnell CJ, de Bakker PI. SNAP: a web-based tool for identification and annotation of proxy SNPs using HapMap. Bioinformatics 2008;24:2938-9.
41. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51.
42. Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet 2008;47:285-95.
43. Blech S, Ebner T, Ludwig-Schwellinger E, Stangier J, Roth W. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos 2008;36:386-99.
44. Eikelboom JW, Wallentin L, Connolly SJ, Ezekowitz M, Healey JS, Oldgren J, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 2011;123:2363-72.
45. American Academy of Pediatrics, Subcommittee on Attention-Deficit/Hyperactivity Disorder Committee on Quality Improvement. Clinical practice guideline: treatment of the school-aged child with attention-deficit/hyperactivity disorder. Pediatrics 2001;108:1033-44.
46. Spencer TJ, Greenbaum M, Ginsberg LD, Murphy WR. Safety and effectiveness of coadministration of guanfacine extended release and psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2009;19:501-10.
47. Sun Z, Murry DJ, Sanghani SP, Davis WI, Kedishvili NY, Zou Q, et al. Methylphenidate is stereoselectively hydrolyzed by human carboxylesterase CES1A1. J Pharmacol Exp Ther 2004;310:469-76.
48. Jefferson T, Jones M, Doshi P, Del MC. Neuraminidase inhibitors for preventing and treating influenza in healthy adults: systematic review and meta-analysis. BMJ 2009;339:b5106.
49. Sweeny DJ, Lynch G, Bidgood AM, Lew W, Wang KY, Cundy KC. Metabolism of the influenza neuraminidase inhibitor prodrug oseltamivir in the rat. Drug Metab Dispos 2000;28:737-41.
50. Widmer N, Meylan P, Ivanyuk A, Aouri M, Decosterd LA, Buclin T. Oseltamivir in seasonal, avian H5N1 and pandemic 2009 A/H1N1 influenza: pharmacokinetic and pharmacodynamic characteristics. Clin Pharmacokinet 2010;49:741-65.
51. Massarella JW, He GZ, Dorr A, Nieforth K, Ward P, Brown A. The pharmacokinetics and tolerability of the oral neuraminidase inhibitor oseltamivir (Ro 64-0796/GS4104) in healthy adult and elderly volunteers. J Clin Pharmacol 2000;40:836-43.
52. Yamanaka K, Takehara N, Murata K, Banno K, Sato T. Pharmacokinetic and pharmacodynamic study of imidaprilat, an active metabolite of imidapril, a new angiotensin-converting enzyme inhibitor, in spontaneously hypertensive rats. J Pharm Biomed Anal 1997;15:1851-9.
53. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502.
54. Sangkuhl K, Klein TE, Altman RB. Clopidogrel pathway. Pharmacogenet Genomics 2010;20:463-5.
55. Shuldiner AR, O'Connell JR, Bliden KP, Gandhi A, Ryan K, Horenstein RB, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. J Am Med Assoc 2009;302:849-57.
56. Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009;373:1849-60.
57. Hankey GJ, Eikelboom JW. Aspirin resistance. Lancet 2006;367:606-17.
58. Marsh S, Hoskins JM. Irinotecan pharmacogenomics. Pharmacogenomics 2010;11:1003-10.